RxDoctor Payments Data

Aaron McPeek, DO

Pain Medicine · Elkton, MDNPI 1063875250

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Abbott at 26.2% of the total.

$2,620in general payments, 2019–2025

Across 122 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$686
  • Saluda Medical Americas, Inc.$391
  • Averitas Pharma Inc.$290
  • Boston Scientific$258
  • Medtronic$184
  • Collegium Pharmaceutical, Inc.$146
  • plus $665 from 17 others

What the payments were for

  • Food & beverage$2,620100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,620 in reported general payments places this provider in the 60th percentile of 144 pain medicine providers in Maryland.

See all pain medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$293,233
Medicare patients
270
Services billed
3,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate14$22,790
Xtampza ErOxycodone Myristate27$17,428
Oxycodone Hcl819$15,914
OxycontinOxycodone Hcl33$11,346
BelbucaBuprenorphine Hcl11$6,567
Lidocaine119$6,429
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen245$6,393
Chlorzoxazone28$6,299
LinzessLinaclotide12$6,237
Pregabalin231$3,805
Gabapentin288$3,610
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$2,714
Morphine Sulfate ErMorphine Sulfate134$2,670
Metaxalone14$2,035
Tizanidine Hcl146$2,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$146$23,99538 claims
PfizerNurtec Odt$17$22,79014 claims
AbbVieLinzess$93$6,23712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 pain medicine providers in Maryland.

Other pain medicine in Elkton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →